Table 2. In Vitro Effects of PF4, NAP-2,... | American Society of Hematology

Table 2.

In Vitro Effects of PF4, NAP-2, and IL-8 on the Survival of Different Types of CB Hematopoietic Progenitors Treated With 5-FU

Treatment of Cells (2.5 × 10⁵)	Total Hematopoietic Progenitors
	After Treatment
	CFU-GEMM	BFU-E	CFU-GM	CFU-MK
1.PBS + PBS	25 ± 3	104 ± 10	145 ± 7	67 ± 4
2.PBS + 5-FU	6 ± 1^†	14 ± 3^†	31 ± 5^†	23 ± 3^†
3.PF4 1 μg/mL + 5-FU	12 ± 2^*	42 ± 5^*	97 ± 4^*	55 ± 3^*
4.NAP-2 0.1 μg/mL + 5-FU	5 ± 1	25 ± 2^*	59 ± 3^*	36 ± 4^*
5.NAP-2 0.6 μg/mL + 5-FU	12 ± 2^*	54 ± 4^*	104 ± 11^*	42 ± 5^*
6.IL-8 0.1 μg/mL + 5-FU	9 ± 2	48 ± 3^*	92 ± 5^*	41 ± 3^*
7.IL-8 0.6 μg/mL + 5-FU	12 ± 1^*	36 ± 4^*	81 ± 3^*	39 ± 3^*
8.Protamine 10 μg/mL + 5-FU	9 ± 2	21 ± 3	42 ± 5	28 ± 4

Treatment of Cells (2.5 × 10⁵)	Total Hematopoietic Progenitors
	After Treatment
	CFU-GEMM	BFU-E	CFU-GM	CFU-MK
1.PBS + PBS	25 ± 3	104 ± 10	145 ± 7	67 ± 4
2.PBS + 5-FU	6 ± 1^†	14 ± 3^†	31 ± 5^†	23 ± 3^†
3.PF4 1 μg/mL + 5-FU	12 ± 2^*	42 ± 5^*	97 ± 4^*	55 ± 3^*
4.NAP-2 0.1 μg/mL + 5-FU	5 ± 1	25 ± 2^*	59 ± 3^*	36 ± 4^*
5.NAP-2 0.6 μg/mL + 5-FU	12 ± 2^*	54 ± 4^*	104 ± 11^*	42 ± 5^*
6.IL-8 0.1 μg/mL + 5-FU	9 ± 2	48 ± 3^*	92 ± 5^*	41 ± 3^*
7.IL-8 0.6 μg/mL + 5-FU	12 ± 1^*	36 ± 4^*	81 ± 3^*	39 ± 3^*
8.Protamine 10 μg/mL + 5-FU	9 ± 2	21 ± 3	42 ± 5	28 ± 4

CB NAMCS (10⁶/mL and 2.5 × 10⁵/well) were preincubated with or without different concentrations of PF4, NAP-2, or IL-8 for 48 hours. 5-FU at 2.5 μg/mL was then added for an additional 24-hour incubation. After incubation, cells were counted, washed 3 times, and then cultured in triplicate at 5 × 10⁴ cells/0.25 mL/well in a 24-well plate in a methylcellulose system containing 10% FCS, recombinant human IL-3 (20 ng/mL), GM-CSF (20 ng/mL), and EPO (4 U/mL) for 14 days for CFU-GEMM, BFU-E, and CFU-GM, and in plasma clot for CFU-MK. Data are expressed as the mean ± SEM from 3 separate experiments.

P < .05 v PBS + 5-FU.

†

P < .05 v PBS + PBS.

View Large

This Feature Is Available To Subscribers Only